A nonstimulant alpha2a-adrenergic receptor agonist originally developed to treat high blood pressure (brand name tenex). An extended-release formulation (brand name intuniv) of guanfacine was approved in 2007 for use in the treatment of attention-deficit/hyperactivity disorder (ADHD).